CD152 [CTLA-4] (mouse):Fc (mouse) (rec.) (non-lytic)
CHI-MF-120A4-C100100 µgCHF 140.00
CHI-MF-120A4-C500500 µgCHF 420.00
CHI-MF-120A4-M0011 mgCHF 600.00
|Sequence||The extracellular domain of mouse CD152 [CTLA-4] (aa 1-160) is fused to the N-terminus of the Fc region of a mutant mouse IgG2a.|
|Biological Activity||Blocks the binding of mouse CD80 (B7-1) and CD86 (B7-2) to their receptors (by binding CD80 and CD86 with high affinity) and thereby prevents their T cell regulatory actions by inhibiting the CD28 signaling competitively. Shows the biological functions of the CD152 moiety and exerts a prolonged circulating half-life caused by the modified Fc domain. Useful for investigating the T cell co-stimulation.|
|Endotoxin Content||<0.06EU/μg protein (LAL test; Lonza).|
|Reconstitution||Reconstitute at 100μg/ml in sterile PBS.|
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS.|
|Other Product Data||
Non-lytic: Acts as a long lasting fusion protein which only binds to the receptor. Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC).
NCBI reference NP_033973.2: CD152 (mouse)
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Avoid freeze/thaw cycles.|
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
CD152 [CTLA-4] and CD28, together with their ligands B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CD152 and CD28 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CD152 and CD28 are composed of a single Ig V-like extracellular domain, a transmembrane domain and an intracellular domain. CD152 and CD28 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. CD152 was originally identified as a gene that was specifically expressed by cytotoxic T lymphocytes. However, CD152 transcripts have since been found in both Th1 and Th2, and CD4+ and CD8+ T cell clones. Whereas, CD28 expression is constitutive on the surfaces of 95% of CD4+ T cells and 50% of CD8+ T cells and is down regulated upon T cell activation, CD152 expression is upregulated rapidly following T cell activation and peaks approximately 24 hours following activation. Although both CD152 and CD28 can bind to the same ligands, CD152 binds to B71 and B72 with 20-100-fold higher affinity than CD28.
- Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance: W. Steurer, et al.; J. Immunol. 155, 1165 (1995)
- CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice : E.A. Tivol, et al.; J. Immunol. 158, 5091 (1997)
- Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation: J.A. Gonzalo, et al.; J. Immunol. 166, 1 (2001)
- Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease: S. Paust, et al.; PNAS 101, 10398 (2004)
- Embryonic Pig Pancreatic Tissue Transplantation for the Treatment of Diabetes: S. Eventov-Friedman, et al.; PLoS Med. 3, e215 (2006)
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses: M.J. Butte, et al.; Immunity 27, 111 (2007)
- Pig Embryonic Pancreatic Tissue as a Source for Transplantation in Diabetes: D. Tchorsh-Yutsis, et al.; Diabetes 58, 1585 (2009)
- Selective CD28 Blockade Attenuates Acute and Chronic Rejection of Murine Cardiac Allografts in a CTLA-4-Dependent Manner: T. Zhang, et al.; Am. J. Transplant. 11, 1599 (2011)